Brinda Balakrishnan/LinkedIn
Dec 22, 2025, 12:39
Shining a Light on von Willebrand Disease: An Often Overlooked Bleeding Disorder
Brinda Balakrishnan, Board Member of Aurinia Pharmaceuticals Inc., shared a post by Star Therapeutics on LinkedIn:
“There continue to be many sizable, rare disorders with few to no therapeutic options. Glad that Star is shining a light on VWD and developing novel medicines to address patient needs!”
Quoting Star Therapeutics‘ post:
“von Willebrand Disease is often overlooked compared to other bleeding disorders like hemophilia, leaving many patients without the resources and support they deserve.
Listen as Nick shares his experience growing up with a condition that was frequently misunderstood and the impact that has had on his journey with VWD.”
Find more related posts on Hemostasis Today.
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question
-
Oct 20, 2026, 04:04Sadia Kamal: Honored to Receive the Outstanding Abstract Award at the 20th Midwest Platelet Conference
-
Oct 20, 2026, 04:03Yu-Hsuan Chen: One Antibody, Two Diseases from FcRn Biology to Clinical Translation
-
Oct 20, 2026, 03:49Domenico Simone Castiello: Rethinking Prolonged DAPT in Multivessel PCI – Insights from the DAPT-MVD Trial
-
Oct 20, 2026, 03:37Rucha Patil: Scaling POC Diagnostics for Haemophilia A and VWD Across India